Prothena Corporation Plc (PRTA) 17.36 $PRTA
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease
GlobeNewswire - Thu Jul 31, 3:12PM CDT
-- First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study
Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 9:55AM CDT
When institutional investors start buying large blocks of shares in a company, it could be a good sign that the stock is getting positive attention because of its potential to move higher. In the last quarter, we saw institutions dramatically...
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
DUBLIN, Ireland , June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has priced an underwritten public offering of 4,750,000 of its ordinary shares at a price to the public of $22.50 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 712,500 ordinary shares.
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Prothena to launch public offering of USD100m ordinary shares
M2 - Tue Jun 24, 4:22AM CDT
Biotechnology company Prothena Corporation plc (NasdaqGS RTA) said on Monday that it plans to begin a public offering of USD100m of its ordinary shares.
Prothena Announces Proposed Offering of Ordinary Shares
Thomson Reuters ONE - Mon Jun 23, 3:20PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
3 Biotech Stocks Falling Like a Knife: Aegerion, Insys, and Prothena
George Budwell, The Motley Fool - Motley Fool - Tue May 27, 5:30PM CDT
Biotech stocks are infamous for their volatility. One wrong step on the clinical or regulatory front can send a company's shares plunging. Adding to their often nauseating ways, biotechs can also recover nearly as fast as they fell, generating...
Prothena to Present at the Jefferies 2014 Global Healthcare Conference in New York
GlobeNewswire - Tue May 27, 3:11PM CDT
Prothena Corporation plc (Nasdaq RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be presenting at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 8:00 AM ET. The conference will be held at The Grand Hyatt New York.
3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.
Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:57AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rise over 27% on the day.
Why Prothena, Galena Biopharma, and Horizon Pharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 4:15PM CDT
Janet Yellen's first chaired Federal Open Market Committee meeting was certainly a memorable one, with the broad-based S&P 500 hiccuping and heading lower after the FOMC announced its latest policy decisions. According to Yellen, the...
Why Prothena (PRTA) Hit an All-Time High Today
at The Street - Wed Mar 19, 1:50PM CDT
Prothena (PRTA) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1....
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis
Thomson Reuters ONE - Tue Mar 18, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease
GlobeNewswire - Thu Jul 31, 3:12PM CDT
-- First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study
Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 9:55AM CDT
When institutional investors start buying large blocks of shares in a company, it could be a good sign that the stock is getting positive attention because of its potential to move higher. In the last quarter, we saw institutions dramatically...
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
DUBLIN, Ireland , June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has priced an underwritten public offering of 4,750,000 of its ordinary shares at a price to the public of $22.50 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 712,500 ordinary shares. Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Prothena to launch public offering of USD100m ordinary shares
M2 - Tue Jun 24, 4:22AM CDT
Biotechnology company Prothena Corporation plc (NasdaqGS
RTA) said on Monday that it plans to begin a public offering of USD100m of its ordinary shares. Prothena Announces Proposed Offering of Ordinary Shares
Thomson Reuters ONE - Mon Jun 23, 3:20PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
3 Biotech Stocks Falling Like a Knife: Aegerion, Insys, and Prothena
George Budwell, The Motley Fool - Motley Fool - Tue May 27, 5:30PM CDT
Biotech stocks are infamous for their volatility. One wrong step on the clinical or regulatory front can send a company's shares plunging. Adding to their often nauseating ways, biotechs can also recover nearly as fast as they fell, generating...
Prothena to Present at the Jefferies 2014 Global Healthcare Conference in New York
GlobeNewswire - Tue May 27, 3:11PM CDT
Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be presenting at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 8:00 AM ET. The conference will be held at The Grand Hyatt New York. 3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.
Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:57AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rise over 27% on the day.
Why Prothena, Galena Biopharma, and Horizon Pharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 4:15PM CDT
Janet Yellen's first chaired Federal Open Market Committee meeting was certainly a memorable one, with the broad-based S&P 500 hiccuping and heading lower after the FOMC announced its latest policy decisions. According to Yellen, the...
Why Prothena (PRTA) Hit an All-Time High Today
at The Street - Wed Mar 19, 1:50PM CDT
Prothena (PRTA) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1....
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis
Thomson Reuters ONE - Tue Mar 18, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
